Abstract
Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally thick and sticky mucus. As a consequence following bacterial infections threaten ten thousands of people around the world every year. Available tests enable early diagnosis of CF. Nevertheless, current treatments can only serve to improve patient’s quality of life. Despite the fact that life span of CF patients is dramatically increased with comprehensive treatments during the last decades, there is no ultimate prevention or cure for CF. Chronic respiratory infections are known to be the major cause of morbidity and mortality. Since the airways provide direct access to these bacteria, it is an attractive target for drug delivery against bacterial infections in CF lung. Current pulmonary treatments are, however, limited since reaching the site of action is highly inhibited by the biofilm, which establishes an efficient obstacle for drug diffusion. Recent developments in nanotechnology have led many researchers to study different types of nanoparticles and nanoformulations for pulmonary drug delivery in the scope of providing a solution to current treatment bottlenecks. This review focuses on the development of nanoparticulate antibiotic pulmonary drug delivery systems for the treatment of Pseudomonas aeruginosa infected CF lungs.
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas aeruginosa, pulmonary nanoparticulate drug delivery.
Drug Delivery Letters
Title:Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Volume: 4 Issue: 3
Author(s): Nazende G. Tureli, Akif E. Tureli and Marc Schneider
Affiliation:
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas aeruginosa, pulmonary nanoparticulate drug delivery.
Abstract: Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally thick and sticky mucus. As a consequence following bacterial infections threaten ten thousands of people around the world every year. Available tests enable early diagnosis of CF. Nevertheless, current treatments can only serve to improve patient’s quality of life. Despite the fact that life span of CF patients is dramatically increased with comprehensive treatments during the last decades, there is no ultimate prevention or cure for CF. Chronic respiratory infections are known to be the major cause of morbidity and mortality. Since the airways provide direct access to these bacteria, it is an attractive target for drug delivery against bacterial infections in CF lung. Current pulmonary treatments are, however, limited since reaching the site of action is highly inhibited by the biofilm, which establishes an efficient obstacle for drug diffusion. Recent developments in nanotechnology have led many researchers to study different types of nanoparticles and nanoformulations for pulmonary drug delivery in the scope of providing a solution to current treatment bottlenecks. This review focuses on the development of nanoparticulate antibiotic pulmonary drug delivery systems for the treatment of Pseudomonas aeruginosa infected CF lungs.
Export Options
About this article
Cite this article as:
G. Tureli Nazende, E. Tureli Akif and Schneider Marc, Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review, Drug Delivery Letters 2014; 4 (3) . https://dx.doi.org/10.2174/2210303104666140222002101
DOI https://dx.doi.org/10.2174/2210303104666140222002101 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Editorial:Tubulin-targeted Cancer Chemotherapeutics: Advances and Challenges
Current Topics in Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry From the Sea to Anticancer Therapy
Current Medicinal Chemistry Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Anti-Cancer Agents in Medicinal Chemistry Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein
Current Topics in Medicinal Chemistry Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Rational Design, Synthesis and Biological Evaluation of Novel Derivatives Based on in vivo Metabolism of Natural Product β-elemene
Letters in Drug Design & Discovery Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets Evidence that Bergapten, Independently of its Photoactivation, Enhances p53 Gene Expression and Induces Apoptosis in Human Breast Cancer Cells
Current Cancer Drug Targets Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Ex Vivo Models of HIV Sexual Transmission and Microbicide Development
Current HIV Research